LOGIN  |  REGISTER
Recursion

Miller Children's & Women's Announces New Miller Children's & Women's Neonatal Network in Partnership with Pediatrix Medical Group, Dr. Antoine Soliman Named Regional Medical Director

November 16, 2023 | Last Trade: US$15.14 2.48 19.59
  • November is Prematurity Awareness Month, Announcement Comes in Celebration of World Prematurity Day on Friday, Nov. 17

LONG BEACH, Calif., Nov. 16, 2023 /PRNewswire/ -- MemorialCare Miller Children's & Women's Hospital Long Beach, along with Pediatrix Medical Group, who has been a long-standing neonatology partner with MemorialCare, have come together to create the Miller Children's & Women's Neonatal Network. This new relationship enables coordinated delivery of provider services to the neonatal intensive care unit (NICU) network establishing a forum for improved communication, financial transparency, and shared program and provider planning. The Neonatal Network will have shared governance between Miller Children's & Women's and Pediatrix, with the neonatologists remaining employees of Pediatrix.

Dr. Antoine Soliman, Regional Medical Director of the Miller Children’s & Women’s Network and Yair Katz, chief executive, Miller Children’s & Women’s

Miller Children's & Women's features a level IV NICU, the highest designation in California, signifying it can care for the sickest and smallest babies. In addition, it has an extremely low birth weight program – caring for babies less than 2 pounds at birth – and has a transport program that allows Miller Children's & Women's the ability to support area community hospitals with smaller and lower acuity maternity and neonatal care.  

"Expanding Miller Children's & Women's Hospital Long Beach as a regional destination for neonatal and pediatric care is an important part of our mission in caring for the most premature and sickest babies, as well as their families," says Yair Katz, chief executive, Miller Children's & Women's. "With all that we are seeing going on in the world today in children's health, we were deeply committed to seeing this through so we can do our part to ensure all babies and their families have access to the highest level of care possible regardless of socioeconomic status."  

To successfully execute this strategic initiative, Miller Children's & Women's has appointed Dr. Antoine Soliman as the Regional Medical Director of the Miller Children's & Women's Network. In this administrative capacity, Dr. Soliman will oversee the performance and quality of the network, lead the onboarding of new sites and serve on the joint operating committee. Dr. Soliman will remain a practicing neonatologist in a limited capacity in Miller Children's NICU, to maintain his direct patient care provider experience. In addition, Dr. Soliman will continue to serve as medical director of the Miller Children's NICU and oversee the recruitment of his replacement for this role.

"I'm deeply honored and humbled to accept the regional directorship of the Miller Children's & Women's Neonatal Network," says Dr. Soliman. "Miller Children's & Women's has made great advances in neonatal care the last few years, graduating healthier babies born quite ill and extremely premature. Our team is remarkable and expanding our capabilities further into the community is paramount to us. I can't think of a better time to announce and launch this partnership, as we celebrate Prematurity Awareness Month and World Prematurity Day later this week."

Miller Children's & Women's, one of eight free standing children's hospitals in California, is unique in that it has a full-service maternity and high-risk program licensed under the children's hospital. This expanded neonatal network will also support regional care by laying the groundwork for recruitment of top talent and bringing access to high-risk maternal and neonatal care into bordering communities' backyards – delivering the highest level of care possible.

About MemorialCare Miller Children's & Women's Hospital Long Beach:

MemorialCare Miller Children's & Women's Hospital Long Beach is a member of MemorialCare, a not-for-profit, integrated health care system. Miller Children's & Women's is one of only eight free-standing children's hospitals in California, is recognized by U.S. News & World Report as a 'Best Children's Hospital' for pediatric pulmonology and lung surgery — treating more than 14,000 children each year — and has become a regional pediatric destination for more than 65,000 children, who need specialized care in outpatient specialty and satellite centers. With maternal-fetal medicine specialists and neonatologists available 24/7, Miller Children's & Women's cares for women with high-risk pregnancies and premature infants under one roof.

About Pediatrix Medical Group

Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation's leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by more than 20 pediatric subspecialties, as well as pediatric primary and urgent care clinics. The group's high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through more than 5,000 affiliated physicians and other clinicians in 37 states. To learn more about Pediatrix, visit www.pediatrix.com or follow us on FacebookInstagramLinkedInTwitter and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.

Astria Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB